Astra Zeneca completes transfer of French sterile manufacturing facility
AstraZeneca has completed the sale of the shares and assets of its sterile manufacturing site located in Monts in France to Scandinavia's largest pharmaceutical contract services provider, Recip Pharma, of Sweden.
The facility in France will be called Recipharm Monts and Michel Saudemon, former AstraZeneca site director, will be the managing director. AstraZeneca will remain a major customer of Recipharm Monts and has committed itself to a long-term activity agreement.
Recip Pharma already has five main manufacturing facilities located in Sweden producing solid dose, semi solids, penicillins and fibre-based products on a contract basis. “This is a major investment for us and a key milestone in our development to becoming one of Europe's leading pharmaceutical services providers,” said Thomas Eldered, executive vice president of Recip.
